Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML

This study has been completed.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: March 15, 2006
Last updated: November 25, 2015
Last verified: November 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2014
  Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)